STOCK TITAN

Palisade Bio, Inc. - $PALI STOCK NEWS

Welcome to our dedicated page for Palisade Bio news (Ticker: $PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palisade Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palisade Bio's position in the market.

Rhea-AI Summary

Palisade Bio's lead product, PALI-2108, has shown promising preclinical results for treating Ulcerative Colitis (UC).

Presented at Digestive Disease Week 2024, data indicates that PALI-2108, an orally administered, colon-specific PDE4 inhibitor, is safe, effective, and well-tolerated in mouse models.

It achieved comparable efficacy to apremilast doses, which are intolerable for human use.

Furthermore, PALI-2108 demonstrated significant improvements in disease activity markers and prevented colon length reduction in a dose-dependent manner.

Notably, it exhibited a large therapeutic window and no systemic toxicity in dog models.

The company plans to commence Phase 1 human trials by year-end 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
-
Rhea-AI Summary

Palisade Bio reported its financial results for Q1 2024 and provided a business update. The company remains on track to commence a Phase 1 clinical study of its lead product, PALI-2108, for treating Ulcerative Colitis (UC) by the end of the year. Financially, Palisade has $11.3 million in cash and recently raised $4 million, ensuring operations can continue until Q1 2025. Net loss increased to $3.5 million from $2.3 million in the same period last year, primarily due to a 78% rise in R&D expenses, driven by costs related to PALI-2108. Key milestones include completing tox studies and nonclinical activities by Q2 and Q3 2024, respectively, and submitting initial IND/CTA in Q3 2024. The company has also formed a strategic collaboration with Strand Life Sciences and has completed significant ex-vivo studies on PALI-2108.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
-
Rhea-AI Summary

Palisade Bio, Inc. announced the appointment of Margery Fischbein to its Board of Directors. Ms. Fischbein, a veteran in Wall Street and the biotech industry, brings expertise in corporate finance, business development, M&A, licensing, and strategic alliance transactions. Her appointment is expected to enhance Palisade Bio's strategy and pipeline of novel therapeutics, particularly in autoimmune, inflammatory, and fibrotic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
management
Rhea-AI Summary

Palisade Bio, Inc. (Nasdaq: PALI) closed a $4 million private placement with an institutional investor for 615,242 shares of common stock, intended for development of PALI-2108 and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent. The company issued unregistered warrants for up to 922,863 shares of common stock with a term of seven years and an exercise price of $6.314 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
-
Rhea-AI Summary

Palisade Bio, a biopharmaceutical company, is raising $4 million through a private placement offering. The company will issue common stock and warrants to an institutional investor at $6.5015 per share. The net proceeds will be used for working capital and general corporate purposes. The closing is expected around May 6, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
-
Rhea-AI Summary

Palisade Bio announced the successful completion of an analysis demonstrating the potent anti-inflammatory effects of PALI-2108 in treating Ulcerative Colitis (UC). The study showed the superior efficacy of PALI-2108 compared to the approved PDE4 inhibitor apremilast, positioning it as a next-generation therapeutic option for inflammatory bowel disease. The company is set to begin Phase 1 human clinical trials before the end of the year, with promising results from the study conducted in collaboration with Paraza Pharma, Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.41%
Tags
none
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life Sciences to advance precision medicine for ulcerative colitis therapy. The partnership grants Palisade Bio access to advanced bioinformatics tools for understanding complex disease pathways and predicting responses to PDE4 inhibitors. Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1600 UC patient samples to identify biomarkers for patient selection using machine learning. This collaboration marks a significant milestone in Palisade Bio's mission to redefine UC treatment through personalized therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.08%
Tags
none
-
Rhea-AI Summary
Palisade Bio successfully demonstrates bioactivation of PALI-2108 in an ex-vivo study of normal healthy and ulcerative colitis patients' stool, showing promising results for the treatment of ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.55%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. (PALI) to present at the Virtual Investor Lunch Break event, featuring an overview by CEO J.D. Finley and CMO Dr. Mitch Jones. The live webcast on April 16, 2024, will focus on the company's business outlook and opportunities in autoimmune, inflammatory, and fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
conferences
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announces the advancement of PALI-2108, a treatment for moderate-to-severe ulcerative colitis, towards Phase 1 clinical study by the end of the year. The company presented at IBD Innovate, discussing the development, differentiation, and clinical pathway of PALI-2108.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.91%
Tags
none
Palisade Bio, Inc.

Nasdaq:PALI

PALI Rankings

PALI Stock Data

4.46M
836.48k
1.75%
15.52%
0.21%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CARLSBAD